Shanghai Shucan Industrial Co.,Ltd
|Place of Origin:||China|
|Minimum Order Quantity:||10 gram|
|Packaging Details:||discreet and safe foil bag or tin|
|Delivery Time:||Within 12hours after payment|
|Payment Terms:||T/T, Western Union, MoneyGram And Bnak transfer|
|Supply Ability:||5000kilogram per month|
|Packing::||As Your Requirement||Place Of Origin:||China|
|Molecular Weight::||2180.33||Purity (HPLC)::||98%min.|
|Appearance ::||White Powder||Single Impurity(HPLC)::||1.0%max|
USP Standard Good Quality Peptides Bivalirudin Trifluoroacetate
Product Name: Bivalirudin Trifluoroacetate
Cas No.: 128270-60-0
Molecular Formula: C98H138N24O33
Molecular Weight: 2180.33
Purity (HPLC): 98.0%min.
Appearance: White Powder
Single Impurity (HPLC): 1.0%max
Amino Acid Composition: ±10% of theoretical
Peptide Content (N%): ≥80.0%
Water Content (Karl Fischer): ≤8.0%
TrifluoroAcetate Content(HPIC): ≤12.0%
MS (ESI): Consistent
Mass Balance: 95.0~105.0%
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
|Minimum order quantity||10gram|
|Supply Ability||mass stock|
|Packaging Details||Discreet25kg/plastic foil or tin bag or as required|
|Lead time||Within 12 hours,upon receipt of your payment cleared|
|Delivery time||Withing 5 working days after the payment cleared ,normally 6 days by air; 15 days by ship|
|Shipping||below 25kg by express, between 25kg~200kg by air, over 200kg by sea|
|Payment Terms||Western Union, Money Gram, T/T, PayPal, Bank Transfer|
|Remarks||Good receipt will be according to time in different countries by means of Air shipment and EXPRESS.|
|Shanghai Shucan Industrial Co.,LTD.|
|lareina (Sales Manger)|
|No.19 Building,28 Lane Beiyu Road,Changning District,Shanghai, China|
Transportation you may like: